Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A note for historians: On April 21, 2026, pancreatic cancer finally began to budge. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.
Jacquelyn Cobb
Associate Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login